title: Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy.
abstract: We recently demonstrated that simultaneous targeting of CD137 co-stimulatory and programmed cell death 1 (PD-1) co-inhibitory molecules synergistically induced an anticancer immune response in the ID8 syngeneic orthotopic mouse ovarian carcinoma model. We further showed that the therapeutic efficacy was enhanced by treatment with cisplatin. These findings provide a rationale for evaluating dual targeting of CD137/PD-1 co-signaling molecules in ovarian cancer patients.
authors: International Joint Cancer Institute; Second Military Medical University; Shanghai, China ; School of Pharmacy; Liaocheng University; Liaocheng, China ; State Key Laboratory of Antibody Medicine & Targeting Therapy and Shanghai Key Laboratory of Cell Engineering & Antibody; Shanghai, China.
authors: Huafeng
authors: H
authors: Wei
authors: School of Bioscience and Bioengineering; South China University of Technology; Guangzhou, China.
authors: Likun
authors: L
authors: Zhao
authors: Department of Pathology; Harborview Medical Center; University of Washington; Seattle, WA USA.
authors: Ingegerd
authors: I
authors: Hellstrom
authors: Department of Pathology; Harborview Medical Center; University of Washington; Seattle, WA USA.
authors: Karl Erik
authors: KE
authors: Hellstrom
authors: International Joint Cancer Institute; Second Military Medical University; Shanghai, China ; School of Pharmacy; Liaocheng University; Liaocheng, China ; State Key Laboratory of Antibody Medicine & Targeting Therapy and Shanghai Key Laboratory of Cell Engineering & Antibody; Shanghai, China ; School of Bioscience and Bioengineering; South China University of Technology; Guangzhou, China.
authors: Yajun
authors: Y
authors: Guo
keywords: CD137; PD-1; co-signaling molecules; immunotherapy; monoclonal antibody; ovarian cancer